drugset / Trial / NCT01516346

Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction

NCT01516346

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity (assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave reflections induced by vasoactive therapy will correlate with the improvement in exercise capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the sustained changes in the reflected wave and other hemodynamic parameters in response to chronic vasodilator therapy.

Timeline

Start
2012-01
Primary completion
2016-02-05
Completion
2017-08-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydralazine Small molecule 75 mg Oral
Comparator Isosorbide Dinitrate Other / unclassified 40 mg Oral